NEW YORK CITY, NY / ACCESS Newswire / March 20, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Picard Medical, Inc. ("Picard" or the "Company") (NYSE:PMI).â?¯â?¯ Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are […]
NEW YORK CITY, NY / ACCESS Newswire / March 20, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against REGENXBIO Inc. ("Regenxbio" or the "Company") (NASDAQ:RGNX).�� Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged
NEW YORK CITY, NY / ACCESS Newswire / March 20, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Plug Power Inc. ("Plug Power" or the "Company") (NASDAQ:PLUG) and certain officers.�� The class action, filed in the United States District Court for the Northern District of New York, and docketed
NEW YORK CITY, NY / ACCESS Newswire / March 20, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Alight, Inc. ("Alight" or the "Company") (NYSE:ALIT).�� Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged
NEW YORK CITY, NY / ACCESS Newswire / March 20, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against uniQure N.V. ("uniQure" or the "Company") (NASDAQ:QURE).�� Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged
NEW YORK CITY, NY / ACCESS Newswire / March 20, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ:RARE).�� Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are
NEW YORK CITY, NY / ACCESS Newswire / March 20, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ:MREO).�� Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail
NEW YORK CITY, NY / ACCESS Newswire / March 20, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Gartner, Inc. ("Gartner" or the "Company") (NYSE:IT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged
NEW YORK CITY, NY / ACCESS Newswire / March 20, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ:CORT).�� Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are
NEW YORK CITY, NY / ACCESS Newswire / March 20, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Trip.com Group Limited ("Trip.com" or the "Company") (NASDAQ:TCOM).�� Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are